NCT01780220View on ClinicalTrials.gov

Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 7, 2022

Study Completion Date

January 7, 2022

Conditions

Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy

Interventions

DRUG

Abiraterone

Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy

Trial Locations (5)

44805

Institut de Cancérologie de l'ouest/René Gauducheau, Saint-Herblain

69373

Centre Leon Berard, Lyon

Unknown

Institut Bergonié, Bordeaux

Centre François Baclesse, Caen

Centre Georges François Leclerc, Dijon

All Listed Sponsors

lead

UNICANCER

OTHER

NCT01780220 - Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery | Biotech Hunter | Biotech Hunter